Santaris Pharma is set to release new clinical data results from the Phase 2a study of miravirsen, the microRNA-targeted drug designed to treat Hepatitis C virus (HCV) infected patients.

Miravirsen, which is developed using the locked nucleic acid (LNA) drug platform, is an inhibitor of miR-122, a liver specific microRNA required for Hepatitis C virus replication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised double-blind placebo-controlled ascending multiple-dose Phase 2a study evaluated the safety and tolerability of miravirsen in treatment-naive patients with chronic HCV genotype 1 infection.

The trial demonstrated that miravirsen can be taken as a once-weekly treatment for chronic HCV infection.

The Phase 2a trial showed the drug provided continuous and prolonged anti-viral activity and was well tolerated in patients infected with HCV.

The company plans to present the study findings at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.